Efficacy and safety of probiotics in IBD: An overview of systematic reviews and updated meta‐analysis of randomized controlled trials

Documenti analoghi

• Upadacitinib Versus Filgotinib in Ulcerative Colitis: Is the Evidence Sufficient to Inform Treatment Decisions?
  di: Sudheer Kumar Vuyyuru, et al.
  Pubblicazione: (2024)
• Vedolizumab for Crohn's disease: Real‐world efficacy through a meta‐analytical lens
  di: Maria Manuela Estevinho, et al.
  Pubblicazione: (2024)
• Defining mucosal healing in randomized controlled trials of inflammatory bowel disease: A systematic review and future perspective
  di: Tommaso Lorenzo Parigi, et al.
  Pubblicazione: (2024)
• Editorial: Striking the Right Balance for Eligibility Criteria for Clinical Trials in Inflammatory Bowel Disease
  di: Virginia Solitano, et al.
  Pubblicazione: (2025)
• IBD 2024: Charting a New Course in IBD Proceedings of the Takeda Symposium 22–23 November 2024 W Hotel, Brisbane, Queensland, Australia
  di: Uma Mahadevan, et al.
  Pubblicazione: (2025)